Gilead Sciences | GILD - Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 41.64B 458M 2026-06
Agios Pharmaceuticals USD 70.22M 11.37M 2026-06
ALKERMES USD 662.09M 62.59M 2026-06
Alnylam Pharmaceuticals USD 1.51B 163.04M 2026-06
Amgen USD 25.5B 547M 2026-06
Biogen USD 3.92B 918.2M 2026-06
BioMarin Pharmaceutical USD 1.66B 870.84M 2026-06
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Coherus Biosciences USD 75.51M 56.82M 2026-06
Eli Lilly USD 47.74B 11.11B 2026-06
Gilead Sciences USD 11.02B 1.54B 2026-06
GlaxoSmithKline GBP 21.53B 895M 2026-06
Glaxosmithkline GBP 22.43B 6.39B 2026-03
Incyte USD 1.31B 177.55M 2026-06
J&J USD 54.9B 2.82B 2026-06
Merck USD 27.73B 786M 2026-06
Moderna USD 2.53B 139M 2026-06
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Novartis USD 31.75B 374M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
PTC Therapeutics USD 771.07M 152.54M 2026-06
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 5.53B 422.9M 2026-06
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sanofi EUR 31.93B 1.92B 2026-06
Sarepta Therapeutics USD 502.91M 3.74M 2026-06
United Therapeutics USD 607.8M 8.7M 2026-06
Vertex Pharmaceuticals USD 3.94B 57.3M 2026-06